Niagen Bioscience (NAGE) 18th Annual Southwest IDEAS Conference summary
Event summary combining transcript, slides, and related documents.
18th Annual Southwest IDEAS Conference summary
19 Nov, 2026NAD science and intellectual property
NAD was presented as essential to cellular energy metabolism and repair; the speaker said Niagen precursors raise cellular NAD and support resilience.
The R&D program has operated for 25 years, with 100+ patents across NAD precursors and 60 specifically related to nicotinamide riboside.
Research base includes 500+ published studies, 52 peer-reviewed human clinical studies on nicotinamide riboside and 300+ research collaborations.
A 200-participant, six-month study found five of seven biological-age clocks showed slowing or reversal after Tru Niagen use, according to the speaker.
Commercial platforms
Tru Niagen was described as a leading single-ingredient supplement; sales include e-commerce, wholesale and ingredient supply to Nestlé brands Solgar and Pure Encapsulations.
Sales mix cited: 60% Tru Niagen e-commerce; ~ $20m wholesale; ~$25m ingredient sales last year; injection/IV business in the $5m–$10m range.
Niagen is offered as an IV or injection; distribution spans 1,700 U.S. clinics, with an at-home kit launched and discussions underway with large telehealth providers.
The U.S. NAD IV market was estimated at $500m; Restore, with 200 locations, made Niagen its flagship ingredient for an October test, extended through December; 2027 growth is anticipated.
NanoCloud skincare launched; discussions with Estée Lauder concern a potential Niagen product in the next few months, alongside talks with other skincare brands.
Pharmaceutical development
Rare-disease targets include ataxia-telangiectasia, Friedreich's ataxia, Cockayne syndrome, Werner syndrome, citrin deficiency and mitochondrial myopathy; two phase II ataxia-telangiectasia studies using Tru Niagen were described as positive.
Development shifted to NB4168, a proprietary prodrug intended to support prescription-drug development across multiple rare disorders.
Estimated incremental cost to reach drug approval is $30m–$40m over ~4 years; licensing, co-financing or spinout deals may occur earlier.
The speaker plans another 6–12 months of work before pursuing partnerships more aggressively; companies have approached, but current terms were viewed as insufficiently compelling.
Orphan-drug vouchers were cited as recently selling for $205m–$210m; potential annual treatment pricing was cited at $400,000–$1m.
Latest events from Niagen Bioscience
- TRU NIAGEN drove 49% FY sales growth, while losses widened and break-even remained a 2019/20 target.NAGE
Q4 2018 - TRU NIAGEN drove 47% FY sales growth as margins improved and global expansion continued.NAGE
Q4 2019 - Q4 growth and stronger margins advanced the path toward break-even.NAGE
Q4 2020 - Consumer expansion and rare-disease development anchor a four-part growth strategy.NAGE
A.G.P. Virtual Consumer Showcase - A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference